Bioorganic & Medicinal Chemistry Letters 22 (2012) 6391-6396

Contents lists available at SciVerse ScienceDirect



Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Serum stability of selected decapeptide agonists of KISS1R using pseudopeptides

Taiji Asami *, Naoki Nishizawa, Yoshihiro Ishibashi, Kimiko Nishibori, Masaharu Nakayama, Yasuko Horikoshi, Shin-ichi Matsumoto, Masashi Yamaguchi, Hirokazu Matsumoto, Naoki Tarui, Tetsuya Ohtaki, Chieko Kitada

Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 2-26-1, Muraoka-higashi, Fujisawa, Kanagawa 251-8555, Japan

ARTICLE INFO

Article history: Received 5 June 2012 Revised 15 August 2012 Accepted 17 August 2012 Available online 23 August 2012

Keywords: Kisspeptin KISS1R agonist Metastin Metastin(45–54) Metastin analog Serum stability

ABSTRACT

Metastin/kisspeptin, a 54-amino acid peptide, is the ligand of the G-protein-coupled receptor KISS1R which plays a key role in pathways that regulate reproduction and cell migration in many endocrine and gonadal tissues. The N-terminally truncated decapeptide, metastin(45–54), has 3–10 times higher receptor affinity and intracellular calcium ion-mobilizing activity but is rapidly inactivated in serum. In this study we designed and synthesized stable KISS1R agonistic decapeptide analogs with selected substitutions at positions 47, 50, and 51. Replacement of glycine with azaglycine (azaGly) in which the α -carbon is replaced with a nitrogen atom at position 51 improved the stability of amide bonds between Phe⁵⁰-Gly⁵¹ and Gly⁵¹-Leu⁵² as determined by in vitro mouse serum stability studies. Substitution for tryptophan at position 47 with other amino acids such as serine, threonine, β -(3-pyridyl)alanine, and p-tryptophan (p-Trp), produced analogs that were highly stable in mouse serum. D-Trp⁴⁷ analog **13** showed not only high metabolic stability using amino acid substitution.

© 2012 Elsevier Ltd. All rights reserved.

Metastin/kisspeptin is the endogenous ligand of an orphan G-protein-coupled receptor GPR54, also known as AXOR12 or OT7T175, and has recently been renamed the KiSS1 receptor (KISS1R).¹⁻³ Recent studies have suggested that metastin acts as a critical potentiator of gonadotropin-releasing hormone secretion following acute administration in several mammalian species including rats,⁴ mice,⁵ and human males,⁶ but lowers testosterone levels as a consequence of continuous administration.⁷ These results strongly suggest that appropriate KISS1R agonists can modulate the hypothalamic-pituitary-gonadal axis and may have the potential to be useful for the prevention or treatment of a number of sex hormone-dependent diseases.

N-terminally truncated human metastin(45–54), Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂, is 3–10 times more active than metastin in vitro.¹ However, both metastin and metastin(45–54) are susceptible to enzyme-catalyzed hydrolysis.⁸ In our laboratory, N^{ω} -methylarginine [Arg(Me)] substitution has been shown to be highly effective in preventing the cleavage between amino acids Arg⁵³ and Phe^{54,9} Consequently, an analog possessing Arg(Me) was synthesized and found to be metabolically resistant to trypsin-like proteases.⁹ There remains a great demand for more stable analogs with other amino acid replacements at fragile sites to improve their pharmacological properties by maintaining or improving agonistic activity and serum stability. In this report, we provide a rational strategy for the design of decapaptide analogs of KISS1R agonists to improve their stability in murine serum.

All peptides were synthesized by standard *N*-(9-fluorenylmethoxycarbonyl;Fmoc)-based solid phase synthetic methodology except where specifically described. The $[Ca^{2+}]_i$ -mobilizing activities of all peptides are shown as the concentration at 50% of the maximum response (EC₅₀ values) calculated using sigmoidal dose response curves in Tables 1 and 2. The receptor binding affinities of the synthesized peptides were determined as IC₅₀ values.

The ability of selected peptides to prevent enzymatic hydrolysis was evaluated by incubation in mouse serum at 37 °C. The residual ratio, defined as the percent of compound remaining after a 1 h incubation at initial concentrations of 0.1 mM, is given in Tables 1 and 2.

Metastin(45–54) was rapidly metabolized in mouse plasma (Fig. 1). More than 50% of the peptide was metabolized after a 1-min incubation at 37 $^{\circ}$ C (data not shown). The metabolites

Abbreviations: Arg(Me), N^ω-methylarginine; azaGly, azaglycine; $[Ca^{2+}]_i$, intracellular calcium concentration; Cha, β-cyclohexylalanine; DMF, dimethylformamide; ESI-MS, electrospray ionization mass spectrometry; FLIPR, fluorometric imaging plate reader; Fmoc, 9-fluorenylmethoxycarbonyl; GnRH, gonadotropinreleasing hormone; HPLC, high-performance liquid chromatography; KISSR, kisspeptin receptor; MBHA, 4-methylbenzhydrylamine; MMP-9, metalloproteinase-9; NEP, neutral endopeptidase; Nal(2), β-(2-naphthyl)alanine; Pya(3), β-(3-pyridyl)alanine; Pya(4), β-(4-pyridyl)alanine; T/C, treated/control; TFA, trifluoroacetic acid.

^{*} Corresponding author. Tel.: +81 466 32 1186; fax: +81 466 29 4453. *E-mail address*: taiji.asami@takeda.com (T. Asami).

⁰⁹⁶⁰⁻⁸⁹⁴X/\$ - see front matter © 2012 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.bmcl.2012.08.069

| Table I |
|---------|
|---------|

| Biological activ | vities of metastin a | analogs substituted | between positions | s 50 and 51 |
|------------------|----------------------|---------------------|-------------------|-------------|

| H-AA ⁴⁵ -Asn-Trp-Asn-Ser-AA ⁵⁰⁻⁵¹ -Leu-AA ⁵³ -Phe-NH ₂ | | | | | | | |
|--|------------------|--------------------------------------|------------------|---|---|-------------------|---------------------------------|
| Compound-no. | AA ⁴⁵ | AA ⁵⁰⁻⁵¹ | AA ⁵³ | Agonist activity ^a EC ₅₀ (nM) | Binding affinity ^c IC ₅₀ (nM) | | Stability in mouse serum |
| | | | | | Human | Rat | Residual ratio (%) ^e |
| Metastin(45-54) | Tyr | Phe-Gly | Arg | 0.049 ^b | 0.082 ^d | 0.11 ^d | ND ^f |
| 1 | D-Tyr | Phe-Gly | Arg(Me) | 0.065 | 0.11 | 0.26 | 18.1 |
| 2 | D-Tyr | Phe- ψ (CSNH)-Gly | Arg(Me) | 0.041 | 2.8 | 3.3 | 35.3 |
| 3 | D-Tyr | Phe- ψ (CH ₂ NH)-Gly | Arg(Me) | 0.62 | 0.61 | 1.4 | 12.1 |
| 4 | D-Tyr | Phe- ψ (NHCO)-Gly | Arg(Me) | 0.95 | 0.51 | 2.9 | 46.8 |
| 5 | D-Tyr | Phe-azaGly | Arg(Me) | 0.050 | 0.16 | 0.17 | 39.5 |

^a Agonist activities of all peptide analogs were evaluated in a functional assay of human OT7T175, an intracellular calcium mobilization assay using fluorometric imaging plate reader technology. EC_{50} values of all peptide analogs were calculated using sigmoidal dose response curves. ^b EC_{50} values of metastic (45–54) were calculated using sigmoidal dose response curves.

EC₅₀ values of metastin(45-54) were calculated as the average value of 13 independent experiments.

с Receptor binding affinities of the synthesized peptides were determined as IC₅₀ values.

^d IC₅₀ value of metastin(45–54) was calculated as the average value of three independent experiments.

^e Residual ratio after incubation in mouse serum 1 h at 37 °C.

^f Not determined.

Table 2

Biological activities of decapeptide metastin analogs substituted at position 47

| H-AA ⁴⁵ -Asn-AA ⁴⁷ -Asn-Ser-Phe-AA ⁵¹ -Leu-AA ⁵³ -Phe-NH ₂ | | | | | | | | |
|---|------------------|----------|------------------|------------------|---|---|-------------------|---------------------------------|
| Compound-no. | AA ⁴⁵ | AA47 | AA ⁵¹ | AA ⁵³ | Agonist activity ^a EC ₅₀ (nM) | Binding affinity ^c IC ₅₀ (nM) Stability | | Stability in mouse serum |
| | | | | | | Human | Rat | Residual ratio (%) ^e |
| Metastin(45-54) | Tyr | Trp | Gly | Arg | 0.049 ^b | 0.082 ^d | 0.11 ^d | ND ^f |
| 6 | D-Tyr | Ser | azaGly | Arg(Me) | 0.73 | 0.49 | 0.43 | 50.0 |
| 7 | D-Tyr | Thr | azaGly | Arg(Me) | 0.24 | 0.86 | 0.83 | 62.5 |
| 8 | D-Tyr | Ile | azaGly | Arg(Me) | 0.13 | 0.43 | 0.46 | ND^{f} |
| 9 | D-Tyr | Cha | azaGly | Arg(Me) | 0.10 | 0.19 | 0.24 | 32.0 |
| 10 | D-Tyr | Pya(3) | azaGly | Arg(Me) | 0.24 | 0.70 | 0.89 | 50.6 |
| 11 | D-Tyr | Pya(4) | azaGly | Arg(Me) | 0.11 | 0.30 | 0.28 | 30.7 |
| 12 | D-Tyr | Nal(2) | azaGly | Arg(Me) | 0.098 | 0.13 | 0.20 | 43.6 |
| 13 | D-Tyr | D-Trp | azaGly | Arg(Me) | 0.072 | 0.19 | 0.22 | 56.4 |
| 14 | D-Tyr | D-Pya(4) | azaGly | Arg(Me) | 0.59 | 0.28 | 0.28 | ND^{f} |

^a Agonist activities of all peptide analogs were evaluated in a functional assay of human OT7T175, an intracellular calcium mobilization assay using fluorometric imaging plate reader technology. EC₅₀ values of all peptide analogs were calculated using sigmoidal dose response curves.

^b EC₅₀ values of metastin(45-54) were calculated as the average value of 13 independent experiments.

с Receptor binding affinities of the synthesized peptides were determined as IC₅₀ values.

 d IC₅₀ value of metastin(45-54) was calculated as the average value of three independent experiments.

^e Residual ratio after incubation in mouse serum 1 h at 37 °C.

^f Not determined.



Figure 1. HPLC chromatogram of metastin(45-54) after incubation in mouse plasma.

formed during incubation were identified by HPLC electrospray ionization mass spectrometry (HPLC-ESI-MS) coupling experiments. ESI mass spectra obtained from metastin(45-54) incubated with mouse plasma revealed the presence of more than ten plausible metabolites as shown in Figure 2. Two major peptide fragments, metastin(46-54) and (46-53), were released primarily as Download English Version:

https://daneshyari.com/en/article/1369460

Download Persian Version:

https://daneshyari.com/article/1369460

Daneshyari.com